

# James R Klinger

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8616148/james-r-klinger-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

2,477  
citations

28  
h-index

49  
g-index

81  
ext. papers

3,201  
ext. citations

5.5  
avg. IF

5.2  
L-index

#	Paper	IF	Citations
73	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	407
72	Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i> , <b>2014</b> , 146, 449-475	5.3	200
71	Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. <i>Cardiovascular Research</i> , <b>2016</b> , 110, 319-30	9.9	142
70	Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 188, 639-46	10.2	130
69	Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2019</b> , 155, 565-586	5.3	126
68	Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. <i>Chest</i> , <b>2001</b> , 120, 866-72	5.3	100
67	Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. <i>Chest</i> , <b>2006</b> , 129, 417-425	5.3	79
66	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	74
65	Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. <i>Chest</i> , <b>1991</b> , 99, 715-23	5.3	74
64	Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. <i>Respiratory Medicine</i> , <b>2005</b> , 99, 1501-10	4.6	70
63	The nitric oxide/cGMP signaling pathway in pulmonary hypertension. <i>Clinics in Chest Medicine</i> , <b>2007</b> , 28, 143-67, ix	5.3	66
62	Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 360-368	10.2	61
61	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. <i>Chest</i> , <b>2017</b> , 151, 468-480	5.3	57
60	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 227-238	35.1	55
59	The Nitric Oxide Pathway in Pulmonary Vascular Disease. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, S71-S79	5.3	54
58	Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. <i>Journal of Applied Physiology</i> , <b>1998</b> , 84, 1646-52	3.7	45
57	Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome. <i>Chest</i> , <b>2002</b> , 121, 656-9	5.3	41

56	Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. <i>Current Opinion in Pharmacology</i> , <b>2005</b> , 5, 245-50	5.1	40
55	Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments. <i>Cardiology Clinics</i> , <b>2016</b> , 34, 413-33	2.5	38
54	Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. <i>Experimental Biology and Medicine</i> , <b>2004</b> , 229, 920-5	3.7	36
53	Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 302-7	3	35
52	Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. <i>Drug Design, Development and Therapy</i> , <b>2009</b> , 3, 269-87	4.4	35
51	Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2002</b> , 282, H58-65 <sup>5.2</sup>	5.2	35
50	Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2135-45	27.4	34
49	Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. <i>Lung</i> , <b>2011</b> , 189, 207-12	2.9	30
48	Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. <i>Experimental Cell Research</i> , <b>2006</b> , 312, 401-10	4.2	30
47	Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>1999</b> , 276, L868-74 <sup>5.8</sup>	5.8	29
46	Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in Rats. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2020</b> , 62, 577-587	5.7	28
45	Pulmonary hypertension in a stable community-based COPD population. <i>Lung</i> , <b>2011</b> , 189, 377-82	2.9	27
44	Inhaled nitric oxide in ARDS. <i>Critical Care Clinics</i> , <b>2002</b> , 18, 45-68, vi	4.5	26
43	Rottlerin causes pulmonary edema in vivo: a possible role for PKCdelta. <i>Journal of Applied Physiology</i> , <b>2007</b> , 103, 2084-94	3.7	25
42	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 573-584	35.1	22
41	WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. <i>Progress in Cardiovascular Diseases</i> , <b>2012</b> , 55, 89-103	8.5	18
40	Guidelines for the Treatment of Pulmonary Arterial Hypertension. <i>Lung</i> , <b>2020</b> , 198, 581-596	2.9	16
39	Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation. <i>Pulmonary Circulation</i> , <b>2016</b> , 6, 191-5	2.7	15

38	Marrow cell infusion attenuates vascular remodeling in a murine model of monocrotaline-induced pulmonary hypertension. <i>Stem Cells and Development</i> , <b>2009</b> , 18, 773-82	4.4	15
37	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. <i>Respiratory Medicine</i> , <b>2017</b> , 122 Suppl 1, S18-S22	4.6	13
36	Initial risk assessment for pulmonary hypertension in patients with COPD. <i>Lung</i> , <b>2012</b> , 190, 83-9	2.9	13
35	C-receptor ligand blocks pulmonary clearance of atrial natriuretic peptide in isolated rat lungs. <i>Experimental Biology and Medicine</i> , <b>1992</b> , 201, 154-8	3.7	9
34	C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade. <i>Life Sciences</i> , <b>2011</b> , 89, 460-6	6.8	8
33	Cardiac atria are the primary source of ANP release in hypoxia-adapted rats. <i>Life Sciences</i> , <b>2010</b> , 87, 382-8	6.8	8
32	Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2014</b> , 15, 502	2.8	7
31	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , <b>2011</b> , 5, 315-28	3.8	7
30	Pulmonary hypertension in the intensive care unit: Critical role of the right ventricle. <i>Critical Care Medicine</i> , <b>2007</b> , 35, 2210-1	1.4	7
29	Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension. <i>Chest</i> , <b>2005</b> , 128, 618S-619S	5.3	7
28	Riociguat: Clinical research and evolving role in therapy. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 2645-2662	3.8	7
27	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	7
26	Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A. <i>Journal of Applied Physiology</i> , <b>2013</b> , 114, 307-15	3.7	6
25	Chronic Thromboembolic Pulmonary Hypertension. <i>Heart Failure Clinics</i> , <b>2018</b> , 14, 339-351	3.3	6
24	Alternative Splicing of the Cardiac Sodium Channel in Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2020</b> , 158, 735-738	5.3	5
23	Culture of pulmonary artery endothelial cells from pulmonary artery catheter balloon tips: considerations for use in pulmonary vascular disease. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	5
22	Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 218-228	4.7	5
21	Low dose 100 cGy irradiation as a potential therapy for pulmonary hypertension. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 21193-21198	7	4

20	Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. <i>Clinics in Chest Medicine</i> , <b>2013</b> , 34, 811-24	5.3	4
19	Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. <i>International Journal of Cardiology</i> , <b>2020</b> , 317, 188-192	3.2	3
18	Rapid development of pulmonary hypertension and right ventricular failure due to large vessel intravascular microcrystalline cellulosis in an intravenous drug user. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020907871	2.7	3
17	Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2014</b> , 4, 45-52	2.7	3
16	Tadalafil in Geriatric Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2010</b> , 138, 367A	5.3	3
15	Pulmonary arterial hypertension: an overview. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , <b>2007</b> , 11, 96-103	1.4	3
14	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211020913	2.7	3
13	Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 761-764	10.2	3
12	Sepsis and Pulmonary Arterial Hypertension in the ICU. <i>Advances in Pulmonary Hypertension</i> , <b>2015</b> , 13, 188-196	0.5	2
11	Modulation of cGMP Synthesis and Metabolism. <i>Respiratory Medicine</i> , <b>2015</b> , 355-375	0.2	1
10	Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020964342	2.7	1
9	Effect of dose, dosing intervals, and hypoxic stress on the reversal of pulmonary hypertension by mesenchymal stem cell extracellular vesicles.. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211046137	2.7	1
8	Novel Pharmacological Targets for Pulmonary Arterial Hypertension. <i>Comprehensive Physiology</i> , <b>2021</b> , 11, 2297-2349	7.7	1
7	Prevalence and risk factors of pulmonary hypertension among adult patients with HIV infection in Ethiopia. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020971518	2.7	0
6	Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.. <i>Pulmonary Circulation</i> , <b>2022</b> , 12, e12055	2.7	0
5	Response. <i>Chest</i> , <b>2019</b> , 156, 187-188	5.3	
4	Ask The Expert: What Are Some Pitfalls and Promises of the Current PAH Treatment Guidelines?. <i>Advances in Pulmonary Hypertension</i> , <b>2017</b> , 15, 182-183	0.5	
3	Pulmonary Arterial Hypertension in Pregnancy <b>2009</b> , 285-312		

- 2 Diagnosis and Management of Pulmonary Hypertension Associated With Pulmonary Fibrosis.  
*Advances in Pulmonary Hypertension*, **2009**, 8, 141-147 0.5
- 1 Transfer of Monocrotaline-Induced Pulmonary Hypertension to Healthy Mice Via Microparticles.  
*Blood*, **2012**, 120, 5190-5190 2.2